Skip to content
WeighLab
Menu
Ranked #105 · Grade C

Novi review

Novi is a compounded GLP-1 telehealth brand advertising semaglutide from $99/month and tirzepatide from $133/month — both framed as marked down from a $299 standing price and paired with a live countdown-timer urgency device.

Visit Novi Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$99/mo (all doses, promotional rate, compounded)
Tirzepatide
$133/mo (all doses, promotional rate, compounded)
Coverage
Coverage not published
Brand-name
Yes

Semaglutide · modeled / year

$1,188

Tirzepatide · modeled / year

$1,596

Pricing verified August 2026

The Index scorecard

Novi scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month87/100
Price Transparency94/100
Nationwide Access24/100
Formulation Options79/100
Clinical Oversight87/100
Contract Flexibility20/100

Where the value is

  • Lowest advertised entry price in this entire batch for both drugs ($99 semaglutide / $133 tirzepatide)
  • LegitScript certified, independently verifiable via the linked legitscript.com record
  • States one flat price per dose with no separate visit fee and free shipping
  • No monthly membership fee and cancel-anytime billing

The tradeoffs

  • No published mg dose, supply duration, state-coverage list, named medical director, or named compounding pharmacy anywhere on the site or its help center — the least transparent operational disclosure of any company researched in this batch
  • The advertised $99/$133 rate is displayed against a live countdown timer ('price increases in...') next to a claimed $299 original price, a scarcity tactic that makes it unclear whether this is a genuine standing rate or a recurring promotional one
  • The Zendesk help center that likely documents dosing and pharmacy details blocks automated/bot access, so this information could not be independently verified

The bottom line

Best for: Shoppers drawn to the lowest flat headline price in this batch, if they're comfortable that dosing, coverage states, and pharmacy details aren't published anywhere on the site. Novi is a compounded GLP-1 telehealth brand advertising semaglutide from $99/month and tirzepatide from $133/month — both framed as marked down from a $299 standing price and paired with a live countdown-timer urgency device.

Ranked #105 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Novi.

The 18 programs nearest this one

Pricing, states and verification reflect Novi's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Novi's site. Not medical advice; see our disclosure.

← Back to the value leaderboard